Profound Medical (NASDAQ:PROF; TSX:PRN) announced that a total of 25 clinical presentations highlighting TULSA procedure’s ability to effectively, safely and efficiently treat an unrivaled variety of prostate cancer and/or benign prostatic hyperplasia (BPH) patients have been made at major medical meetings already in 2024.
The TULSA procedure, performed using Profound’s TULSA-PRO system, employs real-time MR guidance for precision to preserve prostate disease patients’ urinary continence and sexual function while killing the targeted prostate tissue via a precise sound absorption technology that gently heats it to kill temperature (55°C). TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. No hospital stay is required, and most TULSA patients report quick recovery to their normal routine.
“The TACT 5-year clinical trial data, along with multiple real-world reports on the safety, efficacy and durability of TULSA from U.S. commercial centers, such as Mayo Clinic in Florida, Busch Center in Georgia, and UT Southwestern Medical Center in Texas, as well as international user sites, like Sapporo Hokuyu Hospital in Japan, ALTA Klinik in Germany, and Turku University Hospital in Finland, add to the growing body of evidence supporting the potential of TULSA as a mainstream treatment for prostate disease,” said Profound’s CEO and Chairman, Arun Menawat.
Of the 25 TULSA presentations delivered year-to-date, five were given at the European Congress of Radiology (February 29-March 3; Vienna, Austria), one at the Annual Meeting of the Southeastern Section of the American Urological Association (“AUA”) (March 20-23; Austin, TX), three at the Society of Interventional Radiology Annual Scientific Meeting (March 23-28; Salt Lake City, UT), five at the Annual European Association of Urology Congress (April 5-8; Paris, France), one at the Society of Abdominal Radiology Annual Meeting (April 14-19; Hollywood, FL), one at the Japanese Urological Association Annual Meeting (April 25-27; Kobe, Japan), one at the American Roentgen Ray Society Annual Meeting (May 5-9; Boston, MA), and eight at the AUA’s Annual Meeting in San Antonio, TX, which just concluded today.
“The various presentations made at AUA and other major medical conferences have highlighted TULSA’s clinical use across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and BPH; to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer,” Dr. Menawat added.
“Importantly, real-world data from top institutions is also consistently demonstrating similar outcomes to the TACT FDA regulatory study. We would like to take this opportunity to thank the many esteemed researchers and clinicians who have contributed to the growing awareness of TULSA among urologists, both at home and abroad, and look forward to continuing to build on that positive momentum as the year progresses.”
